The Role of FAPI-PET in Evaluating Suspected Liposarcoma: A Case on the Diagnostic Potential

Introduction

The diagnostic evaluation of soft tissue tumors remains a complex task in clinical oncology, particularly when conventional imaging modalities such as MRI or CT scans yield inconclusive results. One area of growing interest is the use of molecular imaging techniques, specifically [⁶⁸Ga]Ga-FAPI-46 PET-CT (FAPI-PET), which targets fibroblast activation protein (FAP) expressed in various tumor stroma [1] [2] [3] [4]. This case highlights the potential role of FAPI-PET in resolving diagnostic uncertainty in a patient with a suspected liposarcoma.

Publikationsverlauf

Eingereicht: 12. Juni 2025

Angenommen nach Revision: 10. September 2025

Artikel online veröffentlicht:
29. September 2025

• References

• 1 van den Hoven AF, Keijsers RGM, Lam M. et al. Current research topics in FAPI theranostics: a bibliometric analysis. Eur J Nucl Med Mol Imaging 2023; 50: 1014-1027
• 2 Gu B, Liu X, Wang S. et al. Head-to-head evaluation of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma. Eur J Nucl Med Mol Imaging 2022; 49: 2889-2901
• 3 Zboralski D, Hoehne A, Bredenbeck A. et al. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging 2022; 49: 3651-3667
• 4 Lanzafame H, Mavroeidi IA, Pabst KM. et al. 68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy. J Nucl Med 2024; 65: 880-887